CULVER CITY, Calif.--(BUSINESS WIRE)--Patrick Soon-Shiong, MD, CEO and founder of NantHealth, has been awarded the Intelligent Health Association (IHA) Special Recognition Award. The award recognizes his leadership in the healthcare technology community and his commitment to transforming cancer care through personalized medicine and combination immunotherapy.
The IHA annual awards identify and recognize the most compelling healthcare projects incorporating wireless technologies resulting in sustainable impact on the patient experience, safety and healthcare facility operations.
Criteria for the award is largely based on significant lifetime achievements in healthcare. As a surgeon, scientist and philanthropist, Dr. Soon-Shiong has dedicated his medical and scientific career to combating life-threatening diseases such as diabetes and cancer. Today, he is leading a collaboration of biotechnology and healthcare leaders on an unprecedented mission to treat cancer with next-generation novel immunotherapies. Earlier in his career, he performed the world's first encapsulated human islet cell transplant in several type I diabetic patients and continued his quest to develop groundbreaking treatments for cancer. Dr. Soon-Shiong invented Abraxane, the nation's first biologically active chemotherapy. The albumin-bound nanoparticle of paclitaxel is designed to enter the tumors micro-environment, which is approved today for the treatment of breast, lung and pancreatic cancer.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter https://twitter.com/DrPatSoonShiong.